Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
AssigneeSociete L'Oreal S.A.
InventorsLionel Breton, Olivier De Lacharriere
Life of this patent
Estimating the term…
Abstract
Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the .alpha.-hydroxy acids, comprise a therapeutically/cosmetically effective amount of at least one calcitonin gene related peptide ("CGRP") antagonist, e.g., CGRP 8-37 or an anti-CGRP antibody.
Claims13
A topically applicable therapeutic/cosmetic composition adopted for the therapeutic treatment or care of sensitive human skin, mucous membranes, and/or the scalp, comprising an effective therapeutically/cosmetically effective amount of at least one calcitonin gene related peptide (CGRP) antagonist and a therapeutically/cosmetically acceptable vehicle, diluent or carrier therefor, and which further comprises at least one normally skin-irritating bioactive agent, and wherein the relative ratio of the amounts of said CGRP antagonist to said bioactive agent in said composition are such that the irritation normally associated with said bioactive agent upon topical application to sensitive skin is inhibited or prevented by said CGRP antagonist.
A regime for therapeutically preventing and/or combating skin irritations and/or dartres and/or erythema and/or dysaesthetic sensations and/or sensations of inflammation and/or pruritis of human skin, scalp, and/or the mucous membranes, comprising topically applying thereto, for such period of time as is required to elicit the desired preventative or therapeutic response, a therapeutically/cosmetically effective amount of at least one CGRP antagonist.
Dependencies are inferred from the claim text.